Denosumab 120mg Injection — RANK Ligand Inhibitor for Bone Metastases and Giant Cell Tumour of Bone
Xgeva® (Denosumab 120mg) — Prevention of Skeletal Related Events in Bone Metastases
The Leading Bone-Targeted Therapy for Cancer Patients with Bone Involvement
Xgeva® (Denosumab 120mg) is a fully human monoclonal antibody that inhibits RANK Ligand (RANKL), used to prevent skeletal related events (SREs) in patients with bone metastases from solid tumours, to treat giant cell tumour of bone (GCTB), and to treat hypercalcaemia of malignancy refractory to bisphosphonate therapy.
A.K. Pharma is a trusted medicine distributor in Delhi supplying genuine Xgeva (Denosumab 120mg) to hospitals, oncology centres, and pharmacies across India. Manufactured by Amgen, Xgeva is one of the most important bone-targeted therapies in oncology practice.
Important: Xgeva (120mg every 4 weeks) is a different product from Prolia (Denosumab 60mg every 6 months) and is used for different indications. Do not substitute one for the other.
What is Xgeva (Denosumab 120mg)?
Xgeva contains Denosumab 120mg — a higher dose than Prolia — administered every 4 weeks for oncology indications. In patients with cancer, tumour cells in bone trigger excessive RANKL expression by stromal cells and osteoblasts, leading to pathological osteoclast activation. This results in bone destruction, pain, fractures, spinal cord compression, and hypercalcaemia — collectively known as skeletal related events (SREs).
By inhibiting RANKL, Xgeva reduces osteoclast-mediated bone destruction in cancer patients, preventing SREs and improving quality of life and survival outcomes.
Full prescribing information is available at the FDA label for Xgeva.
Clinical Studies and Evidence
Study 20050103 (Xgeva vs Zoledronic Acid in Breast Cancer Bone Metastases) Published in The Lancet Oncology (2010), this Phase 3 trial demonstrated Xgeva was superior to Zoledronic Acid in delaying time to first SRE in patients with breast cancer and bone metastases, with a 23% reduction in risk of first on-study SRE.
Study 20050244 (Xgeva vs Zoledronic Acid in Prostate Cancer Bone Metastases) Published in The Lancet (2011), this Phase 3 trial showed Xgeva significantly delayed time to first SRE compared to Zoledronic Acid in patients with castration-resistant prostate cancer and bone metastases.
Study 20050292 (Xgeva vs Zoledronic Acid in Other Solid Tumours) This trial in patients with bone metastases from solid tumours (excluding breast and prostate) and multiple myeloma demonstrated Xgeva was non-inferior to Zoledronic Acid in delaying time to first SRE, with superiority trends in several subgroups.
Giant Cell Tumour of Bone (GCTB) Study Published in The Lancet Oncology (2013), this study demonstrated that Xgeva produced tumour responses in 96% of patients with unresectable or recurrent GCTB, establishing it as the standard treatment for this rare bone tumour.
Available Strengths
Xgeva is available as:
The recommended dose is 120mg subcutaneously every 4 weeks — with additional 120mg doses on days 8 and 15 of the first month for hypercalcaemia of malignancy. Patients should receive calcium and vitamin D supplementation unless hypercalcaemia is present.
Indications — What Xgeva is Used For
Prevention of Skeletal Related Events (SREs)
Giant Cell Tumour of Bone (GCTB)
Hypercalcaemia of Malignancy
For detailed indication information refer to NCI Denosumab Drug Information.
Key Benefits of Xgeva
Superior to Zoledronic Acid in Breast and Prostate Cancer Head-to-head trials demonstrate Xgeva is superior to the previous standard of care (Zoledronic Acid) in delaying SREs in breast and prostate cancer bone metastases — without requiring renal dose adjustment.
No Renal Dose Adjustment Required Unlike Zoledronic Acid (Zometa) which requires dose reduction or is contraindicated in renal impairment, Xgeva can be used at the full dose regardless of renal function — a significant clinical advantage in cancer patients who often have compromised kidney function.
Subcutaneous Administration Xgeva is given as a subcutaneous injection rather than an intravenous infusion, eliminating the need for IV access and infusion chair time.
Effective in GCTB Xgeva is the only approved systemic treatment for unresectable or recurrent Giant Cell Tumour of Bone, producing responses in 96% of patients.
Reduces Pain and Improves Quality of Life By preventing SREs Xgeva reduces bone pain, maintains mobility, and improves quality of life in cancer patients with bone involvement.
How Xgeva Works
In cancer patients with bone metastases the mechanism of bone destruction involves:
In Giant Cell Tumour of Bone:
Xgeva interrupts this cycle by binding to and neutralising RANKL, preventing osteoclast activation and breaking the tumour-bone destruction cycle.
Xgeva vs Prolia vs Zometa — Key Differences
| Feature | Xgeva (Denosumab 120mg) | Prolia (Denosumab 60mg) | Zometa (Zoledronic Acid) |
|---|---|---|---|
| Indication | Bone metastases, GCTB | Osteoporosis | Bone metastases, osteoporosis |
| Dose | 120mg every 4 weeks | 60mg every 6 months | 4mg IV every 3-4 weeks |
| Administration | Subcutaneous injection | Subcutaneous injection | IV infusion (15 minutes) |
| Renal Adjustment | Not required | Not required | Required |
| SRE Reduction vs Zometa | Superior (breast, prostate) | N/A | Standard of care |
| Available at A.K. Pharma | Request Quote | Request Quote | Contact us |
Dosage and Administration
Full dosing guidelines available at Drugs.com Denosumab (Xgeva) Dosage.
Who Should Use Xgeva
Xgeva is prescribed for:
Xgeva is prescribed by oncologists, orthopaedic oncologists, and palliative care physicians. A.K. Pharma supplies Xgeva to oncology centres, hospitals, and pharmacies across Delhi and India.
Possible Side Effects
Common side effects include fatigue, nausea, decreased appetite, dyspnoea, peripheral oedema, and hypocalcaemia.
Serious side effects include:
Full side effect information available at FDA Xgeva Safety Information.
Precautions
Storage and Handling
As a responsible medicine distributor in Delhi, A.K. Pharma maintains strict cold chain requirements during storage and supply of Xgeva, ensuring product integrity for every unit supplied.
Manufacturer Information
Xgeva (Denosumab 120mg) is manufactured by Amgen Inc., a global biotechnology company. Xgeva received FDA approval in November 2010 for prevention of SREs in bone metastases. A.K. Pharma supplies only genuine Xgeva sourced from authorized distributors.
Related Cancer and Bone Medicines Available at A.K. Pharma
Frequently Asked Questions
Q. What is Xgeva used for? Xgeva (Denosumab 120mg) is used to prevent skeletal related events in patients with bone metastases from solid tumours, to treat Giant Cell Tumour of Bone, and to treat hypercalcaemia of malignancy. More information available at NCI Drug Information.
Q. What is the difference between Xgeva and Prolia? Both contain Denosumab but at different doses for different indications. Xgeva (120mg every 4 weeks) is for cancer patients with bone metastases. Prolia (60mg every 6 months) is for osteoporosis. They must not be substituted for each other.
Q. How is Xgeva better than Zoledronic Acid (Zometa)? Xgeva is superior to Zoledronic Acid in delaying SREs in breast and prostate cancer bone metastases based on Phase 3 head-to-head trials. Additionally Xgeva does not require renal dose adjustment, making it preferable in cancer patients with kidney impairment.
Q. Is Xgeva available in India? Xgeva can be supplied to hospitals, oncology centres, and pharmacies across India through licensed pharmaceutical distributors. Contact A.K. Pharma — medicine distributor in Delhi — for availability and pricing.
Q. What is the price of Xgeva in India? Xgeva price in India varies by pack size. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and bulk supply rates.
Q. How to order Xgeva from A.K. Pharma? You can request a quote directly from this page, call us at 011 4172 6999, or WhatsApp us at +91 9810034827 with your requirements and we will respond promptly.
Q. Does A.K. Pharma supply Xgeva in bulk? Yes. A.K. Pharma supplies Xgeva in bulk to oncology centres, hospitals, and pharmacies across Delhi and India. Contact us for bulk pricing and availability.
Why Order Xgeva from A.K. Pharma?
Contact A.K. Pharma for Xgeva Supply 📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052 📞 011 4172 6999 📱 WhatsApp: +91 9810034827 🌐 akpharma.in
